Alizyme of the UK says that it has successfully completed the dose escalation safety stage of a Phase IIa clinical trial evaluating ATL-104 for the treatment of mucositis – a side effect of cancer therapy.
The trial is designed to recruit up to 60 cancer patients in two separate stages. During the first stage at least eight patients in each of three separate cohorts were treated with increasing dose levels of ATL-104 or placebo and a subsequent review identified no safety issues. Stage two is now actively recruiting up to a further 33 patients with randomised administration of each of the three dose levels of ATL-104 or placebo. Full trial results are expected by the end of the year.
Dr Richard Palmer, Alizyme’s chief executive, commented: “In a challenging indication, this trial seeks to demonstrate proof of concept for this novel approach to treating a severe and debilitating side-effect of intensive cancer treatment.”
